Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Document › Details

Immatics N.V.. (10/10/24). "Press Release: Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial". Houston, TX & Tübingen.

Organisations Organisation Immatics N.V. (Nasdaq: IMTX)
  Group Immatics (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product IMA203 TCR-T candidate targeting PRAME (ACTengine)
  Product 2 phase 1 study
Persons Person Britten, Cedrik (Immatics 202006– CMO before GSK VP + Head of Oncology Cell Therapy Research Unit + BioNTech)
  Person 2 Silverstein, Jordan (Immatics 202003 Head of Corporate Strategy before InflaRx + Advanced Accelerator Applications)
     


   
Record changed: 2024-10-10

Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x200px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture biomindz Brand LSE Mainz Place to Biotech 650x300px




» top